CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on ...
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who ...
Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity. SYDNEY, Nov. 2, 2026 /CNW/ -- ...
Protego Biopharma, Inc., a clinical-stage biotechnology company developing small-molecule therapies for protein misfolding ...
(Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and ...
OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and immunological ...
Strong balance sheet, ending the quarter with $1.2 billion in cash and investments. Board authorizes share repurchase program ...
Poster presentations feature preclinical in vitro and in vivo data of potentially first-in-class oral small molecule GIPR ...
A fresh FDA review for Biohaven’s embattled ataxia drug lifted the biotech's shares, while a late-stage lung cancer miss ...
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with ...
Update on discussions with financial partners. Villepinte, November 2, 2026, 8.30 A.m.: Guerbet (FR0000032526 GBT), a global ...
Former biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results